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Summary CA125 is a tumour marker test based on a monoclonal antibody against an antigen from an
ovarian carcinoma cell line. Serum concentrations of CA125 were determined in 95 patients with pancreatic
cancer and in 106 patients with benign pancreatic, biliary and hepatocellular diseases. The CA125
concentrations were compared with the CA19-9 and CEA levels. Almost half (45%) of the patients with
pancreatic cancer had an elevated CA125 level (>35Uml-1). Elevated values were also found in benign
diseases (24%), especially in patients with pancreatitis and benign hepatocellular diseases, but more seldom in
extrahepatic cholestasis. It seems that CA125 is of limited value in the diagnosis of pancreatic cancer.
Combination of the CA125 with the CA19-9 test increases the sensitivity only 6% as compared to the CA19-9
assay alone. There may, however, be a use for CA125 in differentiating between obstructive jaundice of benign
and malignant origin.
The CA125 assay is a new cancer test based on a
monoclonal antibody OC125, which was originally
raised against an epithelial ovarian cancer cell line
(Bast et al., 1981, 1983). The structure of the
antigenic determinant is not completely defined, but
in serum it appears to be associated with a high
molecular weight mucin-like glycoprotein. An
immunoradiometric assay has been developed to
measure the concentrations of CA125 (Bast et al.,
1983, Klug et al., 1984). High concentrations of
CA125 have been found in more than 80 percent of
sera from patients with ovarian cancer, and the test
is especially promising in the follow-up of these
patients (Bast et al., 1983,1984; Canney et al.,
1984). Elevated serum CA125 levels have also been
found in patients with various gastrointestinal
cancers, especially in patients with pancreatic
cancer (59%) (Bast et al., 1983; Klug et al., 1984).
Bast et al. (1983) recorded elevated serum levels
(>35Uml-1) in only one percent of healthy
individuals and six percent of patients with non-
malignant diseases. Ruibal et al. (1984), however,
have reported considerably elevated CA125 values
in patients with various benign diseases, such as
liver cirrhosis (64%), liver granulomatosis (44%),
pancreatitis (38%) and peritonitis (75%).
In this study, the utility of the CA125 test in the
diagnosis and monitoring of patients with
pancreatic cancer was evaluated. The serum levels
from patients with pancreatic cancer were
compared with those from patients with benign
pancreatic, biliary tract and hepatocellular diseases.
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The CA125 levels were also compared with the
concentrations of CA19-9 and CEA.
Patients and methods
Patients
Preoperative serum samples were obtained from 95
patients with pancreatic cancer (9 resectable, and 86
locally spread or metastasized tumours), including
two islet cell carcinomas, one carcinoid tumour,
three cystadenocarcinomas, 2 anaplastic carcinomas,
14 poorly differentiated and 37 well-to-moderately
differentiated ductal adenocarcinomas. The exact
degree of differentiation could not be determined
from available cytological samples in 36 patients
with an adenocarcinoma. Serial samples were
obtained from three radically operated patients,
who later developed a recurrence, and from 7
patients with a nonresectable tumour. Patients who
had received chemotherapy or radiotherapy to the
pancreatic region were not included in the study.
Fifty-two patients had a benign pancreatic
disease: severe haemorrhagic pancreatitis (25
patients), non-haemorrhagic acute pancreatitis (17),
acute pancreatitis associated with pseudocyst
formation (2), and chronic pancreatitis (8). Thirty-
one patients had benign biliary tract diseases:
cholestasis due to stones in the common bile duct
(13 patients) or postoperative stenosis (1), stones in
the bile ducts without jaundice (4), and gallbladder
stones (13). Hepatocellular jaundice was due to
hepatic cirrhosis (9 patients), acute alcoholic
hepatitis (2), or viral hepatitis (12).
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Assays
The serum samples were stored at -20°C or
-70°C from one to 30 months until assayed. The
CA125 concentration in serum was measured using
the Abbott CA125 RIA Diagnostic kit (Abbott,
Wiesbahn, West Germany), and the recommended
cut-off level of 35 Uml- was used (Bast et al.,
1983; Klug et al., 1984). The CAl9-9 concentration
was measured using the CA19-9 RIA kit (Centocor,
Malvern, PA, USA), and the CEA concentration
by a double antibody radioimmunoassay (Rutanen
et al., 1978), or using the Abbott-CEA RIA
Diagnostic kit (Abbott, Wiesbahn, West Germany).
The cut-off values of 37Uml- and 2.5ngml-1
were used for CA19-9 and CEA, respectively. The
results of the CA19-9 and CEA assays in pancreatic
cancer and in benign pancreatico-biliary diseases
have been described earlier (Jalanko et al., 1984,
Haglund et al., 1986).
Results
CA125 in pancreatic cancer
Forty-three of the 95 patients with pancreatic
cancer (45%) had a serum CA125 concentration
above 37Uml-1, and 31% higher than 65Uml-1
(median 28 Uml- 1, range 7.6-5700 Uml-1)(Figure
1, Table I).
High levels were found especially in patients with
widely disseminated cancers. Only 2 out of 9
patients with a resectable pancreatic tumour had
slightly elevated values (Figure 1). The
concentration was increased in 14 patients (38%)
with a well-to-moderately differentiated adeno-
carcinoma, in 8 patients (50%) with a poorly
differentiated or an anaplastic carcinoma, and in 1
of 3 patients with a cystadenocarcinoma. The 2
patients with an islet cell carcinoma and the patient
with a carcinoid tumour had normal CA125 levels.
The serum CA125 levels were serially determined
in 9 cancer patients. Three patients, who underwent
radical surgery had a normal CA125 level before
Figure 1 Serum CA 125 concentrations in patients
with localized (L) and advanced (0) pancreatic
cancer; and with acute (0) and chronic pancreatitis
(A); benign biliary diseases with (0) and without (O)
jaundice and hepatocellular diseases. The cut-off value
35 U/ml for the CA 125 test is indicated by a dashed
line.
operation. In two of these patients the serum level
increased after clinical detection of recurrence
(Figure 2). The CA125 concentration increased with
tumour progression in 2 patients after palliative by-
pass operation, whereas 3 patients had a normal
serum level before and after surgical treatment. The
level decreased during the follow-up in one patient
treated conservatively.
CA125 in benign diseases
Thirteen of the 52 patients (25%) with pancreatitis
Table I Serum CA125 concentrations in patients with pancreatic cancer and with benign
pancreatic, biliary tract and hepatocellular diseases
CA125
Diagnosis No. tested >35 Umr!la >65 UMr-lb >350 Uml-
Pancreatic cancer 95 45% 31% 16%
Pancreatitis 52 25% 17% 0%
Benign biliary disease 31 13% 7% 0%
Hepatocellularjaundice 23 35% 22% 9%
a99% confidence limit for healthy blood donors; b99.8% confidence limit for healthy blood
donors.
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Figure 2 Serial CA125 levels in 3 patients, who + 0 0 _ CO ~ ~ 'T zz *-
underwent pancreatico-duodenectomy for pancreatic E
cancer, and developed a recurrence. The arrows Z Do
indicate the time of clinical verification of the
recurrence. +
-~~ ~~ 00O ZZ O"
had a slightly increased CA125 concentration A
(median 13.5Um 1, range: <7.6-31lUml 1 + +
Only one of 8 patients with chronic pancreatitis k.= r O Hc
showed a slightly elevated CAl125 level. (Figure 1,
e Table I).
+ Elevated CA125 levels were found in 4 patients 0 0000
(13%) with benign biliary disease (median ts a X D- 0~~~~~~~-0 9.0Uml 1 range: <7.6-315U Uml 1Two patients
had a stone in the common bile duct, one with andcv
the other without jaundice, and 2 had acute chole- + +
Cystitiwith jaundice. (Figure 3 , Table( .. COh0
Seven patients with liver cirrhosis and one patient ~~oo
with viral hepatitis had an increased CA125 c
concentration (35%, median 19Uml-1, range:
<7.6-680Uml )(Figure 1, Table I). T E
No correlation between the CA125 concentration
and the bilirubin (r 0.06), alkaline phosphatase
(r=0.03), amylase (r= -0.03) or GOT (r=0.06)A- i levels were seen in this material. C Z ) ..O
>. O (U +>
Comparison of CA125, CA19-9 and CEA
C0)0)~~~
The CA125 levels did not correlate with those of
CAl9-9 (r=0.06)(Figure 3) or CEA (r=0.23). The
assay parameters for the CA125, CA19-9 and CEA
assays, and for the combinations of the tests are
summarized in Table II.900 C. HAGLUND
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Figure 3 Comparison of the CA125 and CAl9-9 concentrations in patients with pancreatic cancer (@) and
with benign pancreatic, biliary tract and hepatocellular diseases (0). The cut-off values for the assays are
marked as dashed lines.
Discussion
Elevated CA125 levels are mainly found in serum
of patients with epithelial ovarian cancer (82%),
but are also reported in 59% in pancreatic cancer
and in 12-32% in various other non-gynaecological
cancers (Bast et al., 1981, 1983; Klug et al., 1984).
In this material less than half (45%) of the patients
with pancreatic cancer showed a value over
35 Uml-1. By using a higher cut-off level of
65Urml-1 (0.2% of healthy blood donors, Bast et
al., 1983) to increase the specificity, the sensitivity
fell to as low as 31%. Only 8% of the patients
with pancreatic cancer had a serum CA 125
concentration higher than any patient with benign
disease. Thus, the low sensitivity limits the use of
the CA125 test in the diagnosis of pancreatic
cancer.
The control group represented differential
diagnostic problems in clinical practice. Elevated
values were found in 24% of these patients,
especially in those with benign liver diseases, as well
as in some patients with pancreatitis. Interestingly,
benign extrahepatic cholestasis, which is the main
cause of false positive values of the CA19-9 and
CEA tests, was only seldom associated with
elevated CA125 levels.
No correlation between the CA125, CA19-9 and
CEA tests was found. Using the recommended cut-
off values the CA125, CA19-9 and CEA tests
showed a similar specificity. The sensitivity of the
CA19-9 assay was clearly highest, but a
combination of the CA125 test with the CA19-9
assay increased the sensitivity only very little, while
the specificity clearly decreased. A specificity close
to 100% (99%) is achieved if an increased
concentration of all three markers occurs.
Unfortunately, only one third of the cancer patients
had an elevated level of all markers, which is too
little for use in clinical practice.
The source of CA125 in serum of patients with
pancreatic cancer is not known. Immunohisto-
chemical staining technique is an appropriate
method of studying the tissue expression of various
cancer-associated antigens (Haglund et al., 1986).
However, the CA125 antigen seems to be destroyed
during paraffin embedding of the tissue specimens
(Kawabat et al., 1983, Haglund et al., unpublished).
Four cryosections from pancreatic carcinomas were
stained, out of which one specimen expressed
CA125 (Haglund et al., unpublished).
Clearly elevated serum levels of CA125 were seen
only in patients with disseminated disease. This
may be due to a large tumour burden, or may
reflect liver involvement, as many of the patients
with benign hepatocellular diseases showed elevated
CA125 levels. This is in concordance with the
findings of Ruibal et al. (1984), who reported
elevated values in patients with liver cirrhosis, liver
granulomatosis, hepatomas and metastatic liver
disease. The elevated serum CA125 levels in liver
processes may be due to a production of CA125 in
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the liver itself or may be caused by a defect of the
liver to metabolize the antigen. It is also possible
that CA125 may partly originate from the
peritoneum in patients with ascites due to benign
liver disease or metastatic disease. The peritoneum,
especially areas of inflammation, is known to
express CA125 (Kawabat et al., 1983) and 75% of
patients with peritonitis have elevated serum CA125
levels (Ruibal et al., 1984).
It seems that CA125 is of little value as a tumour
marker in the primary diagnosis and follow-up of
patients with pancreatic cancer. A combination of
CA125 with CAl9-9 does not increase the
sensititivity of the CA19-9 assay. However, in
patients with obstructive jaundice the CA125 assay
may be helpful in differentiating between malignant
and benign processes.
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